Figure 2 | Scientific Reports

Figure 2

From: Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB

Figure 2

PBRM1 gene mutation predict worse immunotherapy response in NSCLC even with TMB-H. (A) OS levels in ICB treated NSCLC with TMB-H (≥ 10) further stratified according to groups with or without PBRM1 mutation. (B) PFS levels in ICB treated NSCLC with TMB-H (≥ 10) further stratified according to groups with or without PBRM1 mutation. (C) PFS levels of patients stratified according to their PD-L1 expression levels and PBRM1 mutations. PD-L1 low, PD-L1 expression < 1%; PD-L1 high, PD-L1 expression ≥ 1%.

Back to article page